Spectral Diagnostics PE Ratio 2006-2019 | EDTXF
Current and historical p/e ratio for Spectral Diagnostics (EDTXF) from 2006 to 2019. The price to earnings ratio is calculated by taking the latest closing price and dividing it by the most recent earnings per share (EPS) number. The PE ratio is a simple way to assess whether a stock is over or under valued and is the most widely used valuation measure. Spectral Diagnostics PE ratio as of February 28, 2020 is 0.00.
|Spectral Diagnostics PE Ratio Historical Data
||TTM Net EPS
||Medical Instruments Manufacturing
Spectral Medical Inc. develops and commercializes theranostic treatment for severe sepsis. The company's products include Endotoxin Activity Assay, a rapid diagnostic test for detection of components of gram negative bacterial cell wall; and Toraymyxin, a therapeutic hemoperfusion device for the treatment of sepsis that removes endotoxin from the bloodstream. Spectral Medical Inc., formerly known as Spectral Diagnostics Inc., is headquartered in Toronto, Canada.